Glecaprevir/pibrentasvir: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 32: | Line 32: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Glecaprevir_and_pibrentasvir.svg|Glecaprevir and Pibrentasvir | |||
</gallery> | |||
Latest revision as of 22:10, 16 February 2025
Glecaprevir/pibrentasvir is a combination medication used in the treatment of Hepatitis C. It is a combination of two antiviral medications, glecaprevir and pibrentasvir. This medication is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).
Mechanism of Action[edit]
Glecaprevir inhibits the HCV NS3/4A protease, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein. Pibrentasvir inhibits the HCV NS5A protein, which is required for viral replication.
Indications[edit]
Glecaprevir/pibrentasvir is indicated for the treatment of adults with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
Side Effects[edit]
Common side effects of glecaprevir/pibrentasvir include headache and fatigue. Serious side effects may include risk of hepatitis B virus reactivation in patients coinfected with HCV and HBV.
Drug Interactions[edit]
Glecaprevir/pibrentasvir can interact with other drugs and may alter their effectiveness or increase side effects. Some drugs should not be used together with glecaprevir/pibrentasvir.
Dosage[edit]
The recommended dosage of glecaprevir/pibrentasvir is three tablets (total daily dose: glecaprevir 300 mg/pibrentasvir 120 mg) taken orally once daily with food.
Precautions[edit]
Before taking glecaprevir/pibrentasvir, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems.
